NIUMAG QMR06-090H-3 Low-Field Nuclear Magnetic Resonance Analyzer for In Vivo Rodent Lipid Metabolism Studies

Overview

The NIUMAG QMR06-090H-3 is a dedicated benchtop low-field nuclear magnetic resonance (LF-NMR) analyzer engineered for non-invasive, quantitative assessment of lipid metabolism in live rodent models. Unlike high-field MRI systems requiring cryogenic magnets and shielded rooms, this instrument operates at a stable, homogeneous static field of approximately 0.06–0.09 Tesla—optimized for robust T₂ relaxation time discrimination between adipose tissue, lean muscle mass, and free/bound water compartments. Based on the physical principle of proton spin relaxation in hydrogen-rich biological tissues, the system applies calibrated radiofrequency (RF) pulses and measures decay characteristics of the resulting NMR echo train. By applying multi-exponential T₂ decay analysis algorithms, it resolves distinct relaxation components corresponding to fat (short T₂, ~40–100 ms), lean tissue (intermediate T₂, ~10–40 ms), and free water (long T₂, >150 ms). This enables absolute quantification of fat mass (g), lean body mass (g), total body water (mL), and derived ratios—without ionizing radiation, surgical intervention, or contrast agents.

Key Features

• Non-invasive, conscious-animal measurement: Subjects remain awake and unrestrained during acquisition; no anesthesia, sedation, or fasting required—minimizing physiological stress artifacts.
• Rapid single-scan protocol: Full-body composition analysis completed in 60–180 seconds per animal, supporting high-throughput longitudinal studies (e.g., weekly monitoring across 8–12 weeks).
• Validated calibration traceability: Factory-calibrated using phantoms with known fat/water/lean-equivalent relaxivity profiles; optional user-defined calibration with reference standards compliant with ASTM E2917-21 (Standard Practice for Quantitative NMR Analysis).
• Compact, air-cooled permanent magnet architecture: No liquid helium, no RF shielding room; operates in standard laboratory environments (20–25°C, 40–60% RH).
• Dual-mode probe design: Supports both whole-body imaging mode (for regional fat distribution mapping) and dedicated single-point spectroscopy mode (for maximal signal-to-noise ratio in longitudinal metabolic tracking).

Sample Compatibility & Compliance

The QMR06-090H-3 is validated for in vivo analysis of Sprague-Dawley and Wistar rats (150–500 g), C57BL/6 and BALB/c mice (18–40 g), and New Zealand White rabbits (<1.5 kg). Its RF coil geometry accommodates cylindrical sample holders with internal diameters of 35–90 mm, ensuring consistent B₁ homogeneity across species. All measurement protocols adhere to the ARRIVE 2.0 guidelines for reporting animal research. Data output formats (CSV, HDF5) support integration into institutional electronic lab notebooks (ELNs) compliant with 21 CFR Part 11 requirements when paired with validated audit-trail-enabled software configurations. The system does not generate ionizing radiation and requires no radioactive tracers—fully aligned with ICH S5(R3) and OECD 407 testing principles for repeat-dose toxicity studies involving metabolic endpoints.

Software & Data Management

Acquisition and analysis are performed via NIUMAG’s proprietary NMIQ Suite v4.2, a Windows-based application featuring FDA 21 CFR Part 11–ready user access control (role-based permissions), electronic signature capability, and full audit trail logging (user actions, parameter changes, calibration events). Raw FID data is stored in vendor-neutral HDF5 format with embedded metadata (pulse sequence, temperature, coil tuning status). Quantitative outputs include absolute mass values (g), percentage composition, and kinetic T₂ distribution histograms. Batch processing supports automated group-wise statistical comparison (ANOVA, repeated-measures ANOVA) with export to GraphPad Prism, SAS, or R-compatible .RData files. Optional API integration enables direct ingestion into LIMS platforms via RESTful webhooks.

Applications

• Preclinical evaluation of anti-obesity therapeutics: Quantify treatment-induced shifts in fat mass vs. lean mass over time—critical for dose-response modeling and mechanism-of-action validation.
• Nutritional intervention studies: Assess dynamic changes in body composition following high-fat diet challenges, caloric restriction, or micronutrient supplementation.
• Metabolic disease modeling: Characterize phenotypic progression in genetic (e.g., ob/ob, db/db) and diet-induced obesity (DIO) rodent models.
• Toxicology endpoints: Monitor unintended sarcopenia or hepatic steatosis in chronic toxicity studies where body composition serves as a sensitive biomarker.
• Pharmacokinetic-pharmacodynamic (PK-PD) correlation: Link plasma drug concentrations with functional metabolic outcomes measured non-invasively at multiple timepoints.

FAQ

Is anesthesia required during scanning?
No. The system is designed for conscious-animal operation; restraint is limited to gentle manual positioning or use of a ventilated acrylic holder.
Can the instrument distinguish visceral from subcutaneous fat?
Not at the anatomical level—this is a whole-body composition analyzer. For regional fat compartmentalization, high-field MRI or micro-CT remains necessary.
What is the minimum detectable fat mass change?
Based on intra-assay CV ≤1.8% (n=12 repeated scans on same rat), the system reliably detects ≥0.3 g absolute change in fat mass within a 200 g rat.
Does the system comply with ISO/IEC 17025 requirements?
While the instrument itself is not accredited, its measurement methodology aligns with ISO 17025 clause 7.2.2 (validation of non-standard methods); users may establish in-house method validation per ISO/IEC 17025:2017 Annex B.
Is training and service support available internationally?
NIUMAG provides remote application training, on-site installation qualification (IQ), and preventive maintenance contracts through authorized regional partners in EU, North America, and APAC regions.